Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NovaBridge Biosciences's Enterprise Value is €37.00 Mil.
NovaBridge Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-80.96 Mil. Therefore, NovaBridge Biosciences's EV-to-EBIT ratio for today is -0.46.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
NovaBridge Biosciences (FRA:0VY) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
NovaBridge Biosciences's current Enterprise Value is €37.00 Mil.
NovaBridge Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-80.96 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
NovaBridge Biosciences's EV-to-EBITDA for today is:
NovaBridge Biosciences's current Enterprise Value is €37.00 Mil.
NovaBridge Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-80.59 Mil.
NovaBridge Biosciences's current Enterprise Value is €37.00 Mil.
NovaBridge Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
NovaBridge Biosciences's current Enterprise Value is €37.00 Mil.
NovaBridge Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
NovaBridge Biosciences's current Enterprise Value is €37.00 Mil.
NovaBridge Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovaBridge Biosciences Enterprise Value Related Terms
NovaBridge Biosciences Enterprise Value Historical Data
* Premium members only.
The historical data trend for NovaBridge Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0VY vs HUMA, DTIL, ORMP: Enterprise Value Comparison
For the Biotechnology subindustry, NovaBridge Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovaBridge Biosciences Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NovaBridge Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where NovaBridge Biosciences's Enterprise Value falls into.
NovaBridge Biosciences Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
NovaBridge Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovaBridge Biosciences (FRA:0VY) has a Enterprise Value of €37.00 Mil as of Jul. 07, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on NovaBridge Biosciences and its competitors.
Is NovaBridge Biosciences' Enterprise Value too high?
NovaBridge Biosciences' current Enterprise Value is €37.00 Mil. Overall, NovaBridge Biosciences has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' Enterprise Value compare to HUMA and DTIL?
NovaBridge Biosciences' Enterprise Value of €37.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on NovaBridge Biosciences and its competitors. NovaBridge Biosciences's current Enterprise Value is €37.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
Based on GuruFocus' analysis, NovaBridge Biosciences (FRA:0VY) is currently considered Possible Value Trap. The stock's GF Value™ is €37.37, compared to a current price of €1.89 — trading 94.9% below its estimated fair value. The current Enterprise Value is €37.00 Mil. NovaBridge Biosciences' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For NovaBridge Biosciences (FRA:0VY), the current Enterprise Value is €37.00 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovaBridge Biosciences (FRA:0VY) Overvalued in 2026?
Based on GuruFocus' analysis, NovaBridge Biosciences stock appears to be undervalued.
The current stock price of €1.89 is trading 94.9% below its estimated GF Value™ of €37.37.
GuruFocus considers NovaBridge Biosciences to be Possible Value Trap.
Key valuation signals for FRA:0VY:
Enterprise Value: €37.00 Mil
GF Value™: €37.37 vs. price of €1.89 (94.9% below fair value)
No single metric tells the full story. See the FRA:0VY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
37GF Score
Get the complete analysis for FRA:0VY
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0VY has been successfully added to your 
